Nixar 10 mg 30 tablets — Made in Germany — Free Delivery

Nixar is an antihistamine for systemic use.

symptomatic treatment of allergic rhinoconjunctivitis and urticaria.

1 tablet, dispersed in the mouth, contains 10 mg bilastine;

excipients: mannitol, sodium croscarmellose, sodium stearyl fumarate, sucralose (E 955), red grape flavor (main components: gum arabic, ethyl butyrate, triacetin, methyl anthranilate, ethanol, D-limonene, linalool).

Hypersensitivity to the active substance or to any of the excipients listed in the "Composition" section.

The oral dispersed tablet must be placed in the oral cavity where it disperses quickly in saliva, so it can be swallowed easily. Alternatively, an orodispersible tablet may be dispersed in water prior to use. Grapefruit juice or any other fruit juices should not be used for dispersing.

Pediatric population.

Children aged 6 to 11 years with a body weight of at least 20 kg. 10 mg bilastine (1 tablet, dispersed in the mouth) once daily to relieve symptoms of allergic rhinoconjunctivitis (seasonal allergic rhinitis and perennial allergic rhinitis) and urticaria. The oral dispersed tablet should be used 1 hour before or 2 hours after a meal or fruit juice.

Children under 6 years of age weighing up to 20 kg. Bilastine should not be used in this age group.

Adults and adolescents (over 12 years of age) can use 20 mg bilastine tablets.

Pediatric population. Since the efficacy and safety of using bilastine in children under 2 years of age has not been established, and the experience of clinical use in children aged 2 to 5 years is small, bilastine should not be prescribed to these age groups.

In patients with moderate or severe renal impairment, concomitant use of bilastine with P-glycoprotein inhibitors, such as ketoconazole, erythromycin, cyclosporine, ritonavir or diltiazem, can lead to an increase in plasma bilastine levels and, therefore, to an increased risk of side effects. reactions. Therefore, patients with moderate or severe renal impairment should avoid the simultaneous use of bilastine and P-glycoprotein inhibitors.

For safety reasons, it is advisable to avoid taking Nixar® 10 mg during pregnancy.

Since the efficacy and safety of using bilastine in children under 2 years of age has not been established, and the experience of clinical use in children aged 2 to 5 years is small, bilastine should not be prescribed to these age groups.

A study conducted with adults to evaluate the effect of bilastine on the ability to drive vehicles showed that treatment with bilastine 20 mg did not affect driving. However, since the individual response to the drug may vary, patients should be advised to refrain from driving or operating machinery until they know their response to bilastine.

There are no data on overdose in children.

Information on acute overdose of bilastine was obtained during clinical trials conducted in the development with the participation of adults, and post-marketing surveillance. In clinical studies, after prescribing bilastine to 26 healthy adult volunteers at doses 10-11 times higher than the therapeutic one (220 mg as a single dose or 200 mg per day for 7 days), the incidence of adverse reactions was twice as high as during use. placebo. The most commonly reported adverse reactions were dizziness, headache, and nausea. There have been no reports of serious adverse reactions or significant prolongation of the QTc interval. The information collected during post-marketing surveillance is consistent with the data obtained during clinical trials.

Infectious and parasitic diseases - rhinitis.

From the side of the nervous system - headache, dizziness, loss of consciousness.

From the side of the organs of vision - allergic conjunctivitis, eye irritation.

From the gastrointestinal tract - abdominal pain / pain in the upper abdomen, diarrhea, nausea.

On the part of the skin and subcutaneous tissues - eczema, urticaria, swelling of the lips.

No special storage conditions are required.